$6.16
+0.22 (+3.70%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ABEO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 3 observational · 1 with posted results
Held by 8 tracked-famous managers (CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, TWO SIGMA INVESTMENTS, LP, +3 more) · FINRA short interest 12.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 11 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing SettingNCT07700966observationalThe number and incidence of treatment-related malignancies. | — | Recruiting | Combination product: Prademagene Zamikeracel | Recessive Dystrophic Epidermolysis Bullosa | 250 | Apr 2045 | ≤ 6,829 d | 2026-07-14 |
| A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEBNCT05708677observationalWound Closure | — | Enrolling by invitation | Biological: EB-101 | RDEB | 22 | Feb 2036 | ≤ 3,481 d | 2026-07-17 |
| Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of WoundsNCT07717736Study A - Wound Healing ≥50%Non-randomized · Open-label · Treatment | Phase 4 | Not yet recruiting | Biological: Non-conforming pz-cel surgical application to RDEB wounds, Pz-cel surgical application to DEB wounds · Procedure: Additional biopsies | Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB), Dystrophic Epidermolysis Bullosa (DEB) | 100 | Nov 2031 | ≤ 1,929 d | 2026-08-06 |
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsNCT05725018Safety Endpoint (number of treatment-related and treatment-emergent adverse events (AEs) and serious adverse events (SAEs)Open-label · Treatment | Phase 3 | Active, not recruiting | Biological: EB-101 Surgical application of RDEB wounds | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB | 12 | 2025-09-30 | — | 2025-06-27 |
| Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)NCT04227106Wound HealingOpen-label · Treatment | Phase 3 | Completed | Biological: EB-101 | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | 11 | 2022-10-18actual | — | 2022-12-05 |
| Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIBNCT03315182Change from baseline in the Age Equivalent Developmental score (calculated by the Mullen Scales of Early Learning or the Kaufman Assessment Battery for Children Second Edition, based on developmental age) compared with Natural History Study dataNon-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Abeona has decided to discontinue development activities for Product ABO-101 due to a lack of drug supply and for business reasons unrelated to the product safety profile and/or signs of efficacy | Biological: rAAV9.CMV.hNAGLU | Mucopolysaccharidosis Type 3 B | 11 | 2022-04-07actual | — | 2022-05-05 |
| A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101NCT04655911observationalAdverse Events | — | Terminatedsponsor's stated reason: Abeona has decided to discontinue development activities for Product AB0-101 due to a lack of drug supply and for business reasons unrelated to the product safety profile and/or signs of efficacy | Biological: ABO-101 | Mucopolysaccharidosis III-B | 1 | 2022-04-07actual | — | 2022-05-31 |
| Gene Transfer for Recessive Dystrophic Epidermolysis BullosaNCT01263379results2023-07-10Number of Wounds by Healing Category Per Investigator Visual AssessmentOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa | 12 | 2022-03-09actual | — | 2023-08-22 |
| A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great ToenailNCT00385502Determine effectiveness of EcoNail™ lacquer, as determined by effects on nail mycology and appearance, when applied daily for 48 weeks to diseased great toenails in subjects with onychomycosis.Open-label · Treatment | Phase 2 | Completed | Drug: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) | Onychomycosis | 40 | Jun 2008actual | — | 2020-09-03 |
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic UlcersNCT00563394Reduction in clinical signs and symptoms of the infectionRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ofloxacin, MSI-78 | Diabetic Foot Ulcers | 584 | Jul 1996actual | — | 2020-09-03 |
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic UlcersNCT00563433Reduction in clinical signs and symptoms of infectionRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ofloxacin, MSI-78 | Diabetic Foot Ulcers | 342 | Jul 1996actual | — | 2020-09-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19